binoda 500 mg filmsko obložene tablete
gsk d.o.o., ljubljana - kapecitabin - filmsko obložena tableta - kapecitabin 500 mg / 1 tableta - kapecitabin
kapecitabin sandoz 500 mg filmsko obložene tablete
sandoz d.d. - kapecitabin - filmsko obložena tableta - kapecitabin 500 mg / 1 tableta - kapecitabin
kapecitabin zentiva 500 mg filmsko obložene tablete
sanofi-aventis d.o.o. - kapecitabin - filmsko obložena tableta - kapecitabin 500 mg / 1 tableta - kapecitabin
kapecitabin sandoz 150 mg filmsko obložene tablete
sandoz d.d. - kapecitabin - filmsko obložena tableta - kapecitabin 150 mg / 1 tableta - kapecitabin
vopecidex 150 mg filmsko obložene tablete
pharmaswiss Česká republika s.r.o. - kapecitabin - filmsko obložena tableta - kapecitabin 150 mg / 1 tableta - kapecitabin
vopecidex 500 mg filmsko obložene tablete
pharmaswiss Česká republika s.r.o. - kapecitabin - filmsko obložena tableta - kapecitabin 500 mg / 1 tableta - kapecitabin
xalvobin 150 mg filmsko obložene tablete
alvogen ipco s.ar.l - kapecitabin - filmsko obložena tableta - kapecitabin 150 mg / 1 tableta - kapecitabin
xalvobin 500 mg filmsko obložene tablete
alvogen ipco s.ar.l - kapecitabin - filmsko obložena tableta - kapecitabin 500 mg / 1 tableta - kapecitabin
cytosar 1 g prašek za raztopino za injiciranje/infundiranje
pfizer luxembourg sarl - citarabin - prašek za raztopino za injiciranje/infundiranje - citarabin 1 g / 1 viala - citarabin
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - levkemija, limfocitna, kronična, b-celica - antineoplastična sredstva - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.